• PG12 DOSE-RESPONSE RELATION OF INTERFERON-ALPHA IN PATIENTS WITH HBEAG-POSITIVE CHRONIC HEPATITIS B- META-ANALYSIS AND META-REGRESSION OF RANDOMIZED TRIALS

    May 1, 2006, 00:00

  • PCV63 ASSOCIATION OFANTIHYPERTENSIVE MEDICATION CLASS WITH BLOOD PRESSURE CONTROL AND PERSISTENCE ON MONOTHERAPY

    May 1, 2006, 00:00

  • PMH11 A COST-EFFECTIVENESS ANALYSIS MODEL FOR TREATMENT OF CHRONIC SCHIZOPHRENIA IN MEXICO

    May 1, 2006, 00:00

  • PGI11 ECONOMIC BURDEN OF ENDOSCOPY-RELATED INFECTIONS, PSEUDO-INFECTIONS AND TOXIC REACTIONS

    May 1, 2006, 00:00

  • HI4 IMPACT OF PATIENT SELECTION CRITERIA AND MODEL SPECIFICATION ON COMPARISONS OF ALTERNATIVE THERAPIES-THE CASE OF ATYPICAL ANTIPSYCHOTICS

    May 1, 2006, 00:00

  • PNL20 HEALTH CARE ECONOMIC BENCHMARKS FOR MULTIPLE SCLEROSIS IN A COMMERCIAL MANAGED CARE ENVIRONMENT

    May 1, 2006, 00:00

  • PIH11 DEVELOPMENT AND VALIDATION OF THE PREMENSTRUAL SYMPTOMS IMPACT SURVEY

    May 1, 2006, 00:00

  • AC2 THE PREVALENCE OF SUBJECTIVELY EXPERIENCED ADVERSE DRUG REACTIONS. A NATIONWIDE SURVEY IN SWEDEN

    May 1, 2006, 00:00

  • PMC19 EVALUATING THE STRENGTH OF EVIDENCE OF CHANGE- A QUALIFIED CHANGE VS SIMPLE DIFFERENCE APPROACH TO QUALITY OF LIFE RATINGS

    May 1, 2006, 00:00

  • PRO4 PREVALENCE OF MEDICATION COMPLIANCE AND PERSISTENCY WITH SPECIALTY MEDICATIONS IN MANAGED CARE POPULATION

    May 1, 2006, 00:00

  • PIN10 COST EFFECTIVENESS OFTIPRANAVIR IN TREATMENT-EXPERIENCED HIV PATIENTS IN THE USA

    May 1, 2006, 00:00

  • PCN6 HOSPITAL INPATIENT UTILIZATION OF EPOETIN ALFA (EPO) AND DARBEPOETIN ALFA (DARB) IN PATIENTS WITH CANCERAND PRE-DIALYSIS CHRONIC KIDNEY DISEASE (PCKD)

    May 1, 2006, 00:00

  • MH1 NATIONAL TRENDS IN THE DIAGNOSIS OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDERAND USE OF STIMULANTS AMONG CHILDREN IN THE UNITED STATES, 1993-2003

    May 1, 2006, 00:00

  • PIH14 RECALL PERIODS FOR SATISFACTION WITH SEXUAL INTERCOURSE- TWO APPROACHES FOR ASSESSING OUTCOMES

    May 1, 2006, 00:00

  • PG18 A COST-EFFECTIVENESS ANALYSIS OF SCREENING FOR ESOPHAGEAL VARICES- HOW GOOD DOES A CLINICAL DECISION AID HAVE TO BE?

    May 1, 2006, 00:00

  • PNL11 COMPARING APPLES WITH WHAT- DIFFERENT INPUTS AND ASSUMPTIONS PRODUCE DIFFERENT CONCLUSIONS IN MS ECONOMIC MODELS

    May 1, 2006, 00:00

  • PGI10 COST OF ILLNESS IN US EMPLOYEES WITH AND WITHOUT GASTROESOPHAGEAL REFLUX DISEASE

    May 1, 2006, 00:00

  • PAS11 PROPENSITY SCORE MATCHING WITH MORE THAN TWO CATEGORIES

    May 1, 2006, 00:00

  • DB2 SELF REPORTED PREDICTORS OF DEPRESSIVE SYMPTOMATOLOGY IN AN ELDERLY POPULATION WITH TYPE 2 DIABETES MELLITUS

    May 1, 2006, 00:00

  • PCV46 THE ALABAMA COLLABORATION FOR CARDIOVASCULAR EQUALITY PROJECT- ADAPTING AN ELECTRONIC MEDICAL RECORD ABSTRACTION TOOL FOR USE IN AN URBAN COMMUNITY HOSPITAL SETTING

    May 1, 2006, 00:00

  • PCV65 PATIENT ADHERENCE WITH ANTIDIABETIC, ANTIHYPERTENSIVE, AND LIPID-LOWERING MEDICATIONS- EVALUATION OF VETERANS WITH TYPE 2 DIABETES

    May 1, 2006, 00:00

  • PMC22 ALLOCATION OF PRESCRIPTION DATA BY INDICATION- A METHODOLOGY INTEGRATING COMPLEMENTARY PATIENT-LEVEL INFORMATION SOURCES

    May 1, 2006, 00:00

  • POS6 COST OF FALLS IN LONG-TERM CARE FACILITIES (LTCFS)

    May 1, 2006, 00:00

  • PIN13 COST OF THERAPY OF UPPER RESPIRATORY TRACT INFECTIONS IN A DEPRESSED ECONOMY

    May 1, 2006, 00:00

  • PHM2 ECONOMIC AND QUALITY OF LIFE BURDEN OF HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA

    May 1, 2006, 00:00

  • PCN20 COSTS OF THE DIFFERENT TREATMENTS FOR PATIENTS WITH BREAST CANCER IN THE MEXICAN INSTITUTE OF SOCIAL SECURITY (IMSS)

    May 1, 2006, 00:00

  • PHP10 CHARACTERISTICS OF SENIORS WITH HIGH ANNUAL PRESCRIPTION DRUG EXPENDITURES- FINDINGS FROM THE 2002 AND 2003 MEDICAL EXPENDITURE PANEL SURVEY

    May 1, 2006, 00:00

  • PMC21 DEVELOPMENT AND VALIDATION OF A SCALE TO MEASURE PATIENTS'TRUST IN PHARMACISTS IN SINGAPORE

    May 1, 2006, 00:00

  • PMC12 THE COST-EFFECTIVENESS OF BIOLOGIC AGENTS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS- A STRUCTURED REVIEW OF THE LITERATURE

    May 1, 2006, 00:00

  • CS1 THE ECONOMIC AND HEALTH CONSEQUENCES IN SWEDEN OF MANAGING BRADYCARDIA WITH ADAPTA® COMPARED TO A STANDARD DUAL CHAMBER PACEMAKER

    May 1, 2006, 00:00

  • PCV59 LONG-TERM CARDIOVASCULAR OUTCOMES OF COMPLIANCE AND PERSISTENCE WITH HYPERTENSION THERAPY

    May 1, 2006, 00:00

  • PMH25 LEARNING FROM NICE TECHNOLOGY ASSESSMENTS- A CASE STUDY OF ITS RECENT APPRAISAL OF ADHD TREATMENT STRATEGIES

    May 1, 2006, 00:00

  • PAR1 PRESCRIPTION FOR LONGER LIFE- A DIAGNOSIS OF OSTEOARTHRITIS?

    May 1, 2006, 00:00

  • PAR3 RETROSPECTIVE STUDY ON THE ADVERSE EVENTS OF ARTHRITIC PATIENTS TREATED WITH VIOXX AND OTHER ARTHRITIS PAINKILLERS

    May 1, 2006, 00:00

  • PCV33 PRESCRIPTION DRUG INSURANCE STATUS AND UTILIZATION OF ANTI-HYPERLIPIDEMICS- RESULTS FROM THE 2000 MEDICAL EXPENDITURE PANEL SURVEY

    May 1, 2006, 00:00

  • PCV27 THE IMPACT OF DOSE INCREASE ON THE COST-EFFECTIVENESS OF STATINS

    May 1, 2006, 00:00

  • PNL8 ASSESSING THE COST-EFFECTIVENESS OF IMMUNOMODULATORYTHERAPIES FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS BASED ON LONG-TERM DATA

    May 1, 2006, 00:00

  • PCV35 SINGLE SOURCE COST ESTIMATES FOR EVENTS ACROSS VARIOUS CONDITIONS REQUIRING THROMBOEMBOLIC PROPHYLAXIS AND TREATMENT

    May 1, 2006, 00:00

  • PCN13 COST-EFFECTIVENESS ANALYSIS OF APREPITANT IN THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN PATIENTS RECEIVING EITHER CISPLATIN-BASED CHEMOTHERAPY REGIMENS OR MODERATELY EMETOGENIC CHEMOTHERAPY

    May 1, 2006, 00:00

  • CV4 MANAGING CONGESTIVE HEART FAILURE- COHORT ANALYSIS OF USE AND COST OF HOSPITAL, EMERGENCY DEPARTMENT AND OBSERVATION UNIT CARE OVER TWELVE MONTHS

    May 1, 2006, 00:00

  • PMH31 LIKELIHOOD OF EMPLOYMENT TERMINATION FOR EMPLOYEES WITH BIPOLAR DISORDER TREATED WITH DIFFERENT PSYCHOTROPIC MEDICATIONS

    May 1, 2006, 00:00

  • UR2 ECONOMIC BURDEN OF UNTREATED ANEMIA IN PRE-DIALYSIS CHRONIC KIDNEY DISEASE (PCKD) PATIENTS- AN EMPLOYER'S PERSPECTIVE

    May 1, 2006, 00:00

  • The Return on Investment in Health Care- From 1980 to 2000

    May 1, 2006, 00:00

  • PDB30 COSTS AND ADHERENCE ASSOCIATED WITH LONG TERM USE OF THIAZOLIDINEDIONE THERAPY IN MEDICAID ENROLLED TYPE 2 DIABETES PATIENTS

    May 1, 2006, 00:00

  • POB5 THE IMPACT OF BODY MASS INDEX ON HEALTH-RELATED QUALITY OF LIFE AMONG US ADULTS

    May 1, 2006, 00:00

  • PMH48 MEASUREMENT OF UTILITY LOSSES IN DEPRESSION

    May 1, 2006, 00:00

  • PUK2 ASSOCIATION BETWEEN IN-HOSPITAL FALLS, COMORBIDITIES, AND DRUG USE IN ADULT CHRONIC KIDNEY DISEASE PATIENTS- A CASE-CONTROL STUDY

    May 1, 2006, 00:00

  • PIH4 ECONOMIC BURDEN OF ABNORMAL UTERINE BLEEDING- ARE THERE PIECES MISSING?

    May 1, 2006, 00:00

  • HE3 DIFFERENTIAL RACIAL AND ETHNIC DISPARITIES IN HEALTH EXPENDITURE AND SELF-PERCEIVED HEALTH STATUS IN THE UNITED STATES

    May 1, 2006, 00:00

  • PMH32 ANTIPSYCHOTIC THERAPY IN PATIENTS WITH BIPOLAR DISORDER- EFFECTS ON TOTAL AND MENTAL HEALTH CARE COSTS

    May 1, 2006, 00:00

  • PCN39 A SYSTEMATIC REVIEW OF THE UCLA PROSTATE CANCER INDEX'S MEASUREMENT PROPERTIES

    May 1, 2006, 00:00

  • PIN11 THE IMPACT OF MECHANICAL VENTILATION ON OUTCOMES AND COSTS IN NOSOCOMIAL PNEUMONIA

    May 1, 2006, 00:00

  • PDB32 A SYSTEMATIC REVIEW OF ADHERENCE WITH DIABETES TREATMENT AND THE IMPACT OF NON-ADHERENCE ON HEALTH CARE COSTS

    May 1, 2006, 00:00

  • MH4 MEDICAL COSTS AND HOSPTALIZATION OF ADULTS DIAGNOSED WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER WHO RECEIVED ALTERNATIVE THERAPIES

    May 1, 2006, 00:00

  • PCV50 STATIN THERAPY PERSISTENCE IN A MANAGED CARE POPULATION

    May 1, 2006, 00:00

  • PCN23 THE EFFECT OF ORGANIZED MAMMOGRAPHY SCREENING ON THE NUMBER OF BREAST SURGERIES

    May 1, 2006, 00:00

  • PUK10 PSYCHOMETRIC PROPERTIES OF THE KING'S HEALTH QUESTIONNAIRES SYSTEMATIC CRITICAL APPRISAL OF THE LITERATURE

    May 1, 2006, 00:00

  • PHP20 ISPOR CONTRIBUTED RESEARCH 1998-2005- EVALUATION OF TRENDS QUALITY INDICATORS

    May 1, 2006, 00:00

  • PCN45 EFFECT OF AGE ON PREFERENCES FOR HEALTH OUTCOMES IN PROSTATE CANCER

    May 1, 2006, 00:00

  • POS12 PATIENT ADHERENCE WITH BISPHOSPHONATES AT 6 MONTHS- A RETROSPECTIVE COHORT STUDY

    May 1, 2006, 00:00

  • PIN17 A COST-UTILITY ANALYSIS OF PEGINTERFERON ALFA-2A VERSUS PEGINTERFERON ALFA-2B AS THE INITIAL TREATMENT OF HEPATITIS C FROM THE PERSPECTIVE OF THE VETERANS AFFAIRS HEALTH CARE SYSYTEM

    May 1, 2006, 00:00

  • PNL10 COST-EFFECTIVENESS OF MS DISEASE MODIFYING AGENTS- A MARKOV ANDVALUE OF INFORMATION ANALYSIS

    May 1, 2006, 00:00

  • PDB7 COST IMPACT ASSOCIATED WITH INTRODUCTION OF THIAZOLIDINEDIONE THERAPY IN MEDICAID ENROLLED TYPE 2 DIABETES PATIENTS

    May 1, 2006, 00:00

  • PG11 HEPATITIS B IMMUNISATION FOR NEWBORNS OF HEPATITIS B SURFACE ANTIGEN-POSTITIVE MOTHERS- A COCHRANE HEPATO-BILIARY GROUP SYSTEMATIC REVIEW AND META-ANALYSIS

    May 1, 2006, 00:00

  • CV1 INCREMENTAL EXPENDITURE OF TREATING HYPERTENSION IN THE UNITED STATES

    May 1, 2006, 00:00

  • PAR11 WITHDRAWAL OF COX-2 INHIBITOR ROFECOXIBAND VALDECOXIB- IMPACT ON NSAIDAND PPI PRESCRIPTIONS AND EXPENDITURES

    May 1, 2006, 00:00

  • POB4 USE OF GROWTH CURVE ANALYSES FOR DISCRETE EVENT SIMULATION- A CASE STUDY OF POOLED CLINICAL TRIALS OF THE EFFECTS OF RIMONABANT ON CARDIOMETABOLIC RISK FACTORS IN OBESE PATIENTS

    May 1, 2006, 00:00

  • PAS5 RELATIONSHIP OF PATIENT CHARACTERISTICS AND RESOURCE USE IN SEVERE ASTHMA

    May 1, 2006, 00:00

  • PCV4 A NATIONAL STUDY PREDICTING THE INFLUENCE OF PAYMENT SOURCES ON THE THIAZIDE DIURETICS UTILIZATION FOR HYPERTENSION

    May 1, 2006, 00:00

  • PUK14 WORK PRODUCTIVITY IN PATIENTS WITH OVERACTIVE BLADDER- RESULTS FROM THE MATRIX STUDY

    May 1, 2006, 00:00

  • CE2 THE COST-EFFECTIVENESS OF ZEMPLAR IN THE NETHERLANDS

    May 1, 2006, 00:00

  • CN4 COMPARISON OF EPOETIN ALFA AND DARBEPOETIN ALFA TREATMENT COSTS IN AN INPATIENT ONCOLOGY SETTING

    May 1, 2006, 00:00

  • PDB14 MODELLING THE EFFECTIVENESS OF ORAL AGENTS IN ACHIEVING HBAICAND LIPID TARGETS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

    May 1, 2006, 00:00

  • PCN35 DEVELOPMENT AND VALIDATION OF A DISEASE-SPECIFIC, NEUROENDOCRINE TUMOR QUESTIONNAIRE (QOL-NET). TO MEASURE PATIENTS' PERCEPTION OF THE EFFECTS OF DISEASE ON THEIR QUALITY OF LIFE (QOL)

    May 1, 2006, 00:00

  • PHP15 THE CORRELATION OF SATISFACTION OF MEDICARE BENEFICIARIES WITH ACCESS AND QUALITY OF CARE

    May 1, 2006, 00:00

  • PCV43 AN EMPIRICAL EVALUATION OF THE EXPECTED VALUE OF PERFECT INFORMATION

    May 1, 2006, 00:00

  • PCV49 PATIENT ADHERENCE TO AHA GUIDELINES PRE-AND POST AMI

    May 1, 2006, 00:00

  • PCN12 COST-EFFECTIVENESS ANALYSIS OF G-CSF IN ELDERLY PATIENTS WITH AGGRESSIVE NON-HODGKIN'S LYMPHOMA (NHL) RECEIVING CHOP

    May 1, 2006, 00:00

  • PCN26 INTER-RATERAGREEMENT OF HUI3 UTILITY SCORES FOR PATIENTS AT FOUR PHASES OF THERAPY FOR ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDHOOD- PARENT VERSUS CLINICIAN ASSESSMENT

    May 1, 2006, 00:00

  • PNL9 COST-EFFECTIVENESS OFTOPIRAMATE FOR MIGRAINE PREVENTION- A MANAGED CARE PERSPECTIVE

    May 1, 2006, 00:00

  • POS4 COMPARATIVE ANALYSIS OF HEALTH INSURANCE COST OF MEDIAL FEMORAL NECK FRACTURES WITH AND WITHOUT COMPLICATIONS ON A 2 YEARS FOLLOW UP

    May 1, 2006, 00:00

  • PNL19 ECONOMIC BURDEN OF RESTLESS LEGS SYNDROME INA PRIVATELY-INSURED POPULATION

    May 1, 2006, 00:00

  • PHP19 COST SAVINGS ASSOCIATED WITH TABLET SPLITTING PROGRAM IN A PHARMACY BENEFIT MANAGEMENT SETTING

    May 1, 2006, 00:00

  • PNL22 ESTIMATING THE COST OF NURSING HOME CARE FOR PATIENTS WITH PARKINSON'S DISEASE USING RETROSPECTIVE DATABASE ANALYSIS

    May 1, 2006, 00:00

  • PCV22 INPATIENT MANAGEMENT OF TRANSMURAL AND SUBENDOCARDIAL ACUTE MYOCARDIAL INFARCTION (AMI)- DIFFERENCES IN RESOURCE USE AND COST

    May 1, 2006, 00:00

  • PMH18 ANALYZING PATTERNS OF ANTIDEPRESSANT USE AND THE COST CONSEQUENCES OF PRODUCT SWITCHING

    May 1, 2006, 00:00

  • PRO5 PHYSICIAN IMPRESSIONSAND USES OF PATIENT-REPORTED OUTCOMES DATA

    May 1, 2006, 00:00

  • HE4 RACIAL/ETHNIC DISPARITIES IN LENGTH OF STAY AND COST OF INPATIENT CARE FOR INTRACEREBRAL HEMORRHAGE- EVIDENCE FROM THE HEALTH CARE COST AND UTILIZATION PROJECT DATABASE

    May 1, 2006, 00:00

  • PNL12 COST-EFFECTIVENESS OF ELETRIPTAN VERSUS SUMATRIPTAN- RESULTS FROM A RANDOMIZED, CONTROLLED TRIAL

    May 1, 2006, 00:00

  • PMC7 A STANDARDIZED METHODOLOGYTO MEASURE MEDICINE PRICES, AVAILABILITY, AFFORDABILITY AND PRICE COMPONENTS IN DEVELOPING AND TRANSITIONAL COUNTRIES

    May 1, 2006, 00:00

  • PDB39 DIABETIC PATIENTS' PREFERENCE FOR INHALED INSULIN

    May 1, 2006, 00:00

  • PCV62 UNDERSTANDING PATIENT BELIEFS TO DESIGN MEDICATION ADHERENCE MESSAGING

    May 1, 2006, 00:00

  • PMC9 THE USE OF QUINTILE ANALYSIS ASA MEASURE OF DISEASE SEVERITY- A COMPARISON WITHIN AND ACROSS DISEASES

    May 1, 2006, 00:00

  • PDB34 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS–TYPE I AND TYPE 2

    May 1, 2006, 00:00

  • PMC2 HEALTH CONDITIONS IN POSTMENOPAUSAL WOMEN AND IMPLICATIONS FOR THE DESIGN OF CLINICAL TRIALS OF AROMATASE INHIBITORS

    May 1, 2006, 00:00

  • PCV10 LOSS OF COMBINED OPTIMAL LIPID VALUE ACHIEVEMENT AND THE RISK OF CARDIOVASCULAR EVENTS

    May 1, 2006, 00:00

  • PCN27 HEALTH STATUS MEASURES AS PREDICTORS OF MORTALITY AMONG ADULTS WITH BRAIN TUMORS

    May 1, 2006, 00:00

  • PAR18 HEALTH-RELATED QUALITY OF LIFE (HRQL) IN OSTEOARTHRITIS- A SYSTEMATIC REVIEW TO ASSESS THE MEASUREMENT PROPERTIES OFTHEWOMAC (WESTERN ONTARIO MCMASTER OSTEOARTHRITIS INDEX) FOR DISCRIMINATIVE AND EVALUATIVE RESEARCH

    May 1, 2006, 00:00

  • PNL2 RESTLESS LEGS SYNDROME- IDENTIFICATION OF TREATED PATIENTS IN A LARGE CLAIMS DATABASE

    May 1, 2006, 00:00

  • PNL21 PATTERNS OF TOPIRAMATE UTILIZATION AMONG MEDICAID PATIENTS- DIAGNOSIS, COMORBIDITIES AND REAL-WORLD DOSING

    May 1, 2006, 00:00

  • PDB37/DBI- PATIENT-REPORTED UTILITIES/DISUTILITIES ASSOCIATED WITH TREATMENTS FOR TYPE 2 DIABETES

    May 1, 2006, 00:00

  • POB2 COSTS OF PREMATURE DEATH ATTRIBUTED TO OBESITY IN SPAIN

    May 1, 2006, 00:00

  • PCV5 PATIENT RISK ASSESSMENT AND ENGAGEMENT IN PRIMARY CARE MANAGEMENT OF CARDIOVASCULAR RISK

    May 1, 2006, 00:00

  • Abstracts Index

    May 1, 2006, 00:00

  • PCN31 A METHOD TO REMOVE CONTINUOUS ENROLLMENT REQUIREMENT FROM PHARMAECONOMIC STUDIES

    May 1, 2006, 00:00

  • Substantial Returns to Health-Care Spending- But Do We Spend Too Little or Too Much?

    May 1, 2006, 00:00

  • PMH15 BURDEN OF ILLNESS AMONG PATIENTS WITH ALZHEIMER'S DISEASE IN A COMMERCIALLY-INSURED POPULATION

    May 1, 2006, 00:00

  • PCN10 COST-EFFECTIVENESS OF GEMCITABINE-PACLITAXEL COMBINATION IN THE TREATMENT OF ADVANCED BREAST CANCER AFTER FAILURE OF ANTHRACYCLINE THERAPY

    May 1, 2006, 00:00

  • PCV15 ATRIAL VERSUS DUAL CHAMBER PACING IN SINUS NODE DISEASE

    May 1, 2006, 00:00

  • PMC26 CONVERTING SF-36 INTO EQ-5D- DESIGNED TO SUCCEED OR CALCULATED TO FAIL?

    May 1, 2006, 00:00

  • PMH28 SELECTION OF ATYPICAL ANTIPSYCHOTIC MONO-THERAPY FOR PATIENTS WITH BIPOLAR DISORDER- AN ANALYSIS OF A MEDICAID POPULATION

    May 1, 2006, 00:00

  • PNL13 WINNERS AND LOSERS- PATTERNS IN ECONOMIC EVALUATIONS OF ANTI-EPILEPTIC DRUGS

    May 1, 2006, 00:00

  • PUK13 GENERIC VS. DISEASE-SPECIFIC SATISFACTION MEASURES- SELECTING A SATISFACTION MEASURE FOR OVERACTIVE BLADDER STUDIES

    May 1, 2006, 00:00

  • PCV41 PROVISION OF DIET/NUTRITION AND EXERCISE COUNSELING FOR PATIENTS WITH DYSLIPIDEMIA BY AMBULATORY CARE PHYSICIANS IN THE UNITED STATES

    May 1, 2006, 00:00

  • PGI22 WEIGHING TREATMENT BENEFITS AGAINST TREATMENT RISKS- CROHN'S DISEASE PATIENTS'WILLINGNESS TO ACCEPT RISK-BENEFIT TRADEOFFS

    May 1, 2006, 00:00

  • PR5 VALIDATION OF THE HYPERPIGMENTATION TREATMENT SATISFACTION QUESTIONNAIRE (HPTSQ)

    May 1, 2006, 00:00

  • PSM1 POTENTIAL BENEFITS OF SMOKING CESSATION TREATMENT COVERAGE AT THE WORKPLACE

    May 1, 2006, 00:00

  • PIN9 ECONOMIC EVALUATION FORTHE ANTIMICROBIAL EMPIRIC TREATMENT OF HOSPITALIZED PATIENTS WITH VENTILATOR—ASSOCIATED PNEUMONIA DUE TO STAPHYLOCOCCUS AUREUS IN MEXICO

    May 1, 2006, 00:00

  • PAR11 COST-EFFECTIVENESS ANALYSIS FOR TREATMENTS IN ANKYLOSING SPONDYLITIS

    May 1, 2006, 00:00

  • PHP28 THE EFFECT OF HIGH-RISK MEDICATIONS ON VISIT TIME WITH PHYSICIANS- RESULTS FROM THE NAMCS SURVEY

    May 1, 2006, 00:00

  • PMH7 ANNUAL COSTS ASSOCIATED WITH PATTERNS OF ANTIDEPRESSANT TREATMENT RESPONSE AMONG EMPLOYEES

    May 1, 2006, 00:00

  • PHP4 OUT-OF-POCKET PRICE OF OUTPATIENT MEDICATIONS IN THE UNITED STATES

    May 1, 2006, 00:00

  • PGI19 OBJECTIVE MEASUREMENT OF PRODUCTIVITY WHILE AT WORK IN US EMPLOYEES WITH AND WITHOUT GASTROESOPHAGEAL REFLUX DISEASE

    May 1, 2006, 00:00

  • PHP17 IMPACT OF CO-PAY DIFFERENTIAL ON GENERIC PRESCRIPTIONS FILLED THROUGH 90-DAY RETAIL CHANNEL

    May 1, 2006, 00:00

  • PMH39 COMPARATIVE ANALYSIS OF DISCONTINUATION HAZARD FOR ATYPICAL ANTIPSYCHOTICS

    May 1, 2006, 00:00

  • PCV16 ROSUVASTATIN IS MORE COST-EFFECTIVE COMPARED TO ATORVASTATIN AND SIMVASTATIN FOR HYPERLIPIDEMIA MANAGEMENT IN HIGH-RISK PATIENTS IN ROUTINE CLINICAL PRACTICE

    May 1, 2006, 00:00

  • PCN18 CLINICAL AND ECONOMIC OUTCOMES OF INITIAL ACUTE MYELOBLASTIC LEUKEMIA (AML) HOSPITALIZATION IN THE ELDERLY

    May 1, 2006, 00:00

  • Where's the Value in Health Care?

    May 1, 2006, 00:00

  • PCN46 ONLINE REPORTING OFTOXICITY SYMPTOMS BY LUNG CANCER PATIENTS DURING CHEMOTHERAPY

    May 1, 2006, 00:00

  • PAS4 ECONOMETRIC MODELING IN CHRONIC ASTHMA ALLOWS COMPARISONS BETWEEN DIFFERENT THERAPY GROUPS

    May 1, 2006, 00:00

  • PR8 THE IMPACT OF ABNORMAL UTERINE BLEEDING ON HEALTH-RELATED QUALITY OF LIFE- A META-ANALYSIS

    May 1, 2006, 00:00

  • PIN20 COMPARISON OF HEALTH OUTCOMES AMONG SEVERE COMMUNITY-ACQUIRED PNEUMONIA PATIENTS TREATED EMPIRICALLY WITH A BETA-LACTAM PLUS A MACROLIDE VERSUS A BETA-LACTAM PLUS A FLUOROQUINOLONE

    May 1, 2006, 00:00

  • PCV66 A SYSTEMATIC REVIEW OF THE DISEASE-SPECIFIC AND THE GENERIC QUALITY-OF-LIFE INSTRUMENTS IN CONGESTIVE HEART FAILURE

    May 1, 2006, 00:00

  • PUK11 ESTIMATING A PREFERENCE-BASED SINGLE INDEX FROM THE OVERACTIVE BLADDER QUESTIONNAIRE

    May 1, 2006, 00:00

  • PCV60 IMPACT OF ADHERENCE TO ANTIHYPERLIPIDEMIC DRUGS ON TOTAL PHARMACY AND MEDICAL COSTS

    May 1, 2006, 00:00

  • PSK2 PHYSICIAN AND PATIENT RELATED DETERMINANTS OF PRESCRIBING TOPICAL CALCINEURIN INHIBITORS FOR PATIENTS WITH ATOPIC DERMATITIS- ANALYSIS OF U.S. NATIONAL OUTPATIENTVISIT DATA

    May 1, 2006, 00:00

  • PMH37 COMPARING ADHERENCE AND PERSISTENCE WITH ANTIPSYCHOTIC THERAPY AMONG PATIENTS WITH BIPOLAR DISORDER

    May 1, 2006, 00:00

  • PNL24 THE ESTIMATION POWER OF ALTERNATIVE COMORBIDITY INDEXES

    May 1, 2006, 00:00

  • PG17 COST-EFFECTIVENESS (C-E) OFTEGASEROD VS. PLACEBO FOR TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C)

    May 1, 2006, 00:00

  • PCV18 ECONOMIC EVALUATION OF ORAL THERAPIES FOR PULMONARY ARTERIAL HYPERTENSION

    May 1, 2006, 00:00

  • PCV68 BENEFICIAL IMPACT ON BLOOD PRESSURE CONTROL AMONG MEN PRESCRIBED SILDENAFIL CITRATE

    May 1, 2006, 00:00

  • PDB15 COST-UTILITY ANALYSIS OF ANALOG BASAL BOLUS THERAPY AMONG INSULIN-DEPENDENT DIABETES PATIENTS

    May 1, 2006, 00:00

  • PGI20 SUBJECTIVE REASONS FOR NONCOMPLIANCE WITH MEDICATION REGIMEN IN INFLAMMATORY BOWEL DISEASE PATIENTS

    May 1, 2006, 00:00

  • PCV25 USE OF COMPLEMENTARY AND ALTERNATIVE MEDICINE BY HYPERTENSIVE PATIENTS IN THE UNITED STATES

    May 1, 2006, 00:00

  • PEY6 REAL-WORLD UTILIZATION PATTERNS OF CYCLOSPORINE OPHTHALMIC EMULSION 0.05% WITHIN MANAGED CARE

    May 1, 2006, 00:00

  • ID1 “GATEKEEPERS AND SENTINELS”- IMPLICATIONS FOR DRUG UTILIZATION POLICY IN THE COMMUNITY SETTING

    May 1, 2006, 00:00

  • PCN42 PREDICTIVE VALUE OF SERIAL MEASUREMENTS OF QUALITY OF LIFE ON ALL-CAUSE MORTALITY IN PROSTATE CANCER PATIENTS- DATA FROM CAPSURE™

    May 1, 2006, 00:00

  • HE1 ECONOMIC EVALUATION OF A 90-DAY RETAIL PRESCRIPTION DRUG PROGRAM IN A PHARMACY BENEFIT MANAGEMENT SETTING

    May 1, 2006, 00:00

  • CS3 THE EFFECT OF ORGAN THREATENING AND MENTAL HEALTH CO-MORBIDITIES ON MEDICAL COSTS IN SYSTEMIC LUPUS ERYTHEMATOSUS

    May 1, 2006, 00:00

  • PCV53 STATIN NONCOMPLIANCE AFTER CHD HOSPITALIZATION AND SUBSEQUENT HOSPITALIZATION AMONG NEW STATIN USERS

    May 1, 2006, 00:00

  • POS11 THE USE OF INDIVIDUAL RISKS RATHER THAN POPULATION AVERAGES IN COST-EFFECTIVENESS MODELING

    May 1, 2006, 00:00

  • PEY5 ECONOMIC EVALUATION OF PHOTODYNAMIC THERAPY (VISUDYNE®) COMPARED TO USUAL CARE IN THE TREATMENT OF AGE RELATED MACULAR DEGENERATION (ARMD) IN USA

    May 1, 2006, 00:00

  • PGI21 ADHERENCE AND RIBAVIRIN DOSE AS CRITICAL SUCCESS FACTORS TO THE CHRONIC HEPATITIS C (CHC) TREATMENT- A CROSS SECTIONAL EVALUATION IN BRAZIL

    May 1, 2006, 00:00

  • RS1 TRENDS IN MEDICATION PRESCRIBING FOR CHILDREN WITH SLEEP DISORDERS IN US OUTPATIENT SETTINGS

    May 1, 2006, 00:00

  • PAR10 COST-EFFECTIVENESS OF RITUXIMAB THERAPY FOR RHEUMATOID ARTHRITIS- A PAN-EUROPEAN ANALYSIS

    May 1, 2006, 00:00

  • PUK5 EPOETIN ALFA AND DARBEPOETIN ALFA DOSING PATTERNS IN ANEMIC PRE-DIALYSIS CHRONIC KIDNEY DISEASE PATIENTS

    May 1, 2006, 00:00

  • CS2 ECONOMIC BURDEN OF WORK LOSS AMONG SUFFERERS OF LYMPHATIC FILARIASIS- AN ERADICABLE GLOBAL HEALTH PROBLEM

    May 1, 2006, 00:00

  • PCN38 PROPENSITY SCORE MATCHING WITH LIMITED OVERLAP

    May 1, 2006, 00:00

  • PDB12 A MARKOV MODEL TO ASSESS THE COST-EFFECTIVENESS OF A CONTINUOUS GLUCOSE MONITORING SYSTEM WITH TRENDING AND RATE INFORMATION WHEN USED TO PREDICT AND PREVENT HYPO-AND HYPERGLYCEMIA IN PATIENTS WITH TYPE I DIABETES

    May 1, 2006, 00:00

  • PMC8 AN INTERACTIVE ECONOMIC MODEL FOR VACUUM ASSISTED CLOSURE THERAPY

    May 1, 2006, 00:00

  • PCNI5 THE ANNUAL HEALTH INSURANCE COST OF COLORECTAL CANCER TREATMENT IN HUNGARY-A COST OF ILLNESS STUDY

    May 1, 2006, 00:00

  • PMH24 INCREASING FORMULARY ACCESS TO INNOVATIVE DRUGS- EFFECTS ON THE TREATMENT FOR SCHIZOPHRENIA IN A MEDI-CAL POPULATION

    May 1, 2006, 00:00

  • PNL31 HEALTHCARE UTILIZATION AND PATIENT SATISFACTION WITH TRIPTAN TREATMENT IN MIGRAINEURS

    May 1, 2006, 00:00

  • PMH41 PREDICTORS OF SWITCHING ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA

    May 1, 2006, 00:00

  • CE3 SHORT-TERM COST-EFFECTIVENESS OF RECOMBINANT ACTIVATED FACTOR VII IN THE TREATMENT OF INTRACEREBRAL HEMORRHAGE

    May 1, 2006, 00:00

  • PRO3 EVALUATION OF A PROGRAM TO IMPROVE ADHERENCE WITH PEGYLATED INTERFERON THERAPY- A PROPENSITY SCORE MATCHED RETROSPECTIVE COHORT ANALYSIS

    May 1, 2006, 00:00

  • AC1 USING TABLET PCS FOR SMOKING HAZARDS EDUCATION IN A METHADONE CLINIC

    May 1, 2006, 00:00

  • PMH13 AN ECONOMIC COST ANALYSIS OF ATYPICAL ANTIPSYCHOTIC SINGLE TREATMENT FOR BIPOLAR DISORDER IN A MEDICAID PROGRAM

    May 1, 2006, 00:00

  • PHP24 ELECTRONIC INTERFACES FOR SHARING PATIENT DATA- ESTIMATING RETURN ON INVESTMENT IN HOSPICE

    May 1, 2006, 00:00

  • PSU2 THE SHORT TERM COST-EFFECTIVENESS OF 45 SURGICAL INTERVENTIONS IN THE UK

    May 1, 2006, 00:00

  • PAS10 A SYSTEMATIC OVERVIEW OF THE MEASUREMENT PROPERTIES OF THE ST. GEORGE'S RESPIRATORY QUESTIONNAIRE IN ASTHMA

    May 1, 2006, 00:00

  • PMC15 INTERNET-BASED UTILITY ELICITATION OF A GENERIC HEALTH STATE

    May 1, 2006, 00:00

  • PMH30 EVALUATION OF SELECTIVE SEROTONIN REPUTAKE INHIBITOR STEP CARE PROGRAM ON MEDICATION COSTS AND UTILIZATION

    May 1, 2006, 00:00

  • CN3 COLONOSCOPY PROCEDURE RATES AMONG PRIVATE-PAY PATIENTS INCREASED SUBSTANTIALLY BETWEEN 2000 AND 2004

    May 1, 2006, 00:00

  • PMC1 TRANSFERABILITY OF ECONOMIC EVALUATIONS- CAN RESULTS FROM ONE GEOGRAPHIC AREA BE USED TO HELP INFORM HEALTH CARE DECISION MAKING IN ANOTHER?

    May 1, 2006, 00:00

  • PMH10 COST AND EFFECTIVENESS OF SWITCHING FROM RISPERIDONE TO OLANZAPINE IN THE TREATMENT OF SCHIZOPHRENIA

    May 1, 2006, 00:00

  • PMH9 COST-EFFECTIVENESS OF ATYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF ACUTE MANIA

    May 1, 2006, 00:00

  • HI3 THE EFFECTS OF STATIN (HMG-COA REDUCTASE INHIBITOR) COPAYMENTS AND STATIN ADHERENCE ON MEDICAL CARE OUTCOMES AND EXPENDITURES

    May 1, 2006, 00:00

  • PCV47 AN APPROACH TO GENERALIZE CLINICAL TRIAL RESULTS TO NON-STUDY POPULATIONS FOR COST-EFFECTIVENESS EVALUATIONS—THE CASE OF THE COLLABORATIVE ATORVASTATIN DIABETES STUDY (CARDS)

    May 1, 2006, 00:00

  • PCV52 MEDICATION ADHERENCE- PREDICTORS AND IMPACT ON HOSPITALIZATION RISK

    May 1, 2006, 00:00

  • PDB16 BASAL BOLUS THERAPY AMONG TYPE I DIABETES PATIENTS- A COMPARATIVE COST-EFFECTIVENESS ANALYSIS OF ANALOG-AND HUMAN-BASED INSULIN REGIMENS

    May 1, 2006, 00:00

  • PIN2 COST COMPARISON OF A ONCE-DAILY PARENTERAL ANTIBIOTIC IN HOSPITAL SETTINGS- INFORMATION FROM THE SIDESTEP STUDY

    May 1, 2006, 00:00

  • POS5 THE COST-EFFECTIVENESS OF IBANDRONATE IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS IN THE US

    May 1, 2006, 00:00

  • PCN8 COST-EFFECTIVENESS OF ADJUVANT CHEMOTHERAPY WITH URACIL-TEGAFUR, AN ORAL FLUOROPYRIMIDINE DERIVATIVE, IN PATIENTS WITH NON-SMALL-CELL LUNG CANCER IN JAPAN

    May 1, 2006, 00:00

  • PCV34 DEVELOPING HOSPICE DRUG FORMULARY USING MULTI-ATTRIBUTE UTILITYTHEORY (MAUT) METHODOLOGY

    May 1, 2006, 00:00

  • PHP25 HEALTH-RELATED QUALITY OF LIFE ASSESSMENT IN PHARMACEUTICAL CARE- EVALUATING PHARMACIST'S KNOWLEDGE, UNDERSTANDING AND PERCEIVED BARRIERS IN PHARMACY PRACTICE

    May 1, 2006, 00:00

  • PCN33 MAPPING FACT-PAND EORTC QLQ-C30TOTHE EQ-5D HEALTH UTILITY IN METASTATIC HORMONE-REFRACTORY PROSTATE CANCER PATIENTS

    May 1, 2006, 00:00

  • MH2 USE PATTERNS AND OUTCOMES ASSOCIATED WITH TYPICAL DEPOT ANTIPSYCHOTIC AGENTS IN THE SCHIZOPHRENIA CARE ASSESSMENT PROGRAM (SCAP)—AUSTRALIA

    May 1, 2006, 00:00

  • POS13 COMPLIANCE, DISCONTINUATION, AND SWITCHING OF OSTEOPOROSIS TREATMENT IN LOUISIANA MEDICAID POST-MENOPAUSAL WOMEN

    May 1, 2006, 00:00

  • PCN5 QUALITY IN HEALTH CARE SERVICES FOR WOMEN WITH BREAST CANCERAND ITS ECONOMIC CONSEQUENCES IN MEXICO

    May 1, 2006, 00:00

  • PCV2 RETROSPECTIVE STUDY OF PATIENTS WITH CABG REOPERATION AND OUTCOMES

    May 1, 2006, 00:00

  • PMH26 REVIEW ON HEALTH OUTCOMES ASSOCIATED WITH DEPOT ANTIPSYCHOTIC AGENTS AND LONG-ACTING RISPERIDONE INJECTABLE (LARI) FOR TREATMENT OF SCHIZOPHRENIA

    May 1, 2006, 00:00

  • PMH42 COMPLIANCE AND PERSISTENCE- A COMPARISON BETWEEN TYPICAL AND ATYPICAL ANTIPSYCHOTIC TREATMENT OF SCHIZOPHRENIA PATIENTS

    May 1, 2006, 00:00

  • PCN2 EFFECTIVENESS OF A COMMUNITY—BASED PROSTATE CANCER EDUCATION KIOSK FOR AFRICAN AMERICAN MEN- ANALYSES OF COST, SATISFACTION, QUALITY, KNOWLEDGE, AND INTENTION VARIABLES

    May 1, 2006, 00:00

  • PHP8 BRITISH COLUMBIAN PHYSICIANS' OPINIONS REGARDING REFERENCE DRUG AND GENERIC SUBSTITUTION PROGRAMS

    May 1, 2006, 00:00

  • UR1 THE ECONOMIC IMPACT OF EPOETIN ALFA (EPO) THERAPY ON DELAYING TIME TO DIALYSIS IN ELDERLY PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD)

    May 1, 2006, 00:00

  • Cost-Effectiveness of Olanzapine as First-Line Treatment for Schizophrenia- Results from a Randomized, Open-Label, 1-Year Trial

    Mar 1, 2006, 00:00

  • Validation of Electronic Data Capture of the Irritable Bowel Syndrome—Quality of Life Measure, the Work Productivity and Activity Impairment Questionnaire for Irritable Bowel Syndrome and the EuroQol

    Mar 1, 2006, 00:00

  • The Instrumental Variable Method to Study Self-Selection Mechanism- A Case of Influenza Vaccination

    Mar 1, 2006, 00:00

  • Cost-Effectiveness of Fondaparinux Compared with Enoxaparin as Prophylaxis against Venous Thromboembolism in Patients Undergoing Hip Fracture Surgery

    Mar 1, 2006, 00:00

  • Psychometric Evaluation of a New Questionnaire Measuring Treatment Satisfaction in Hypothyroidism- The ThyTSQ

    Mar 1, 2006, 00:00

  • Incorporating Direct and Indirect Evidence Using Bayesian Methods- An Applied Case Study in Ovarian Cancer

    Mar 1, 2006, 00:00

  • Performance of the EQ-5D in Patients with Irritable Bowel Syndrome

    Mar 1, 2006, 00:00

  • Determinants of Health Economic Decisions in Actual Practi The Role of Behavioral Economics

    Mar 1, 2006, 00:00

  • A Primer on Dynamic Optimization and Optimal Control in Pharmacoeconomics

    Mar 1, 2006, 00:00

  • Developing Better Economic Models of Osteoporosis- Considerations for the Calculation of the Relative Risk of Fracture

    Jan 1, 2006, 00:00

  • Measurement of HRQL Using EQ-5D in Patients with Type 2 Diabetes Mellitus in Japan

    Jan 1, 2006, 00:00

  • Systematic Screening for Chlamydia trachomatis- Estimating Cost-Effectiveness Using Dynamic Modeling and Dutch Data

    Jan 1, 2006, 00:00

  • Pramipexole versus Levodopa in Patients with Early Parkinson's Disease- Effect on Generic and Disease-Specific Quality of Life

    Jan 1, 2006, 00:00

  • The New Injury Severity Score- Better Prediction of Functional Recovery after Musculoskeletal Injury

    Jan 1, 2006, 00:00

  • Discrepancies between Patient-Reported Outcomes and Clinician-Reported Outcomes in Chronic Venous Disease, Irritable Bowel Syndrome, and Peripheral Arterial Occlusive Disease

    Jan 1, 2006, 00:00

  • A Comparison of Depressive Symptoms in Stroke and Primary Care- Applying Rasch Models to Evaluate the Center for Epidemiologic Studies-Depression Scale

    Jan 1, 2006, 00:00

  • Economic Evaluation of Voriconazole versus Conventional Amphotericin B in the Treatment of Invasive Aspergillosis in Germany

    Jan 1, 2006, 00:00

  • PCN32 COST-EFFECTIVENESS ANALYSIS OF LETROZOLE VERSUS TAMOXIFEN AS INITIAL ADJUVANT THERAPY IN HORMONE-RECEPTOR POSITIVE POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER IN THE UK

    Nov 1, 2005, 00:00

  • PIH2 THE COST OF PREMATURITY- TWO NEONATAL INTENSIVE CARE UNITS (NICUS) FROM UNIVERSITY HOSPITALS OF ATHENS

    Nov 1, 2005, 00:00

  • CN2 COST-EFFECTIVENESS OFTEMOZOLOMIDE FORTHE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME IN THE UK

    Nov 1, 2005, 00:00

  • PRS17 QUALITY OF LIFE IN COPD- HOW CAN WE MEASURE IT?

    Nov 1, 2005, 00:00

  • PMH49 QUALITY OF LIFE IN MAJOR DEPRESSION- RESULTS OF THE MC4 TRIAL

    Nov 1, 2005, 00:00

  • PMH4 ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS- MENTAL HEALTH AND PHYSICAL CO-MORBIDITY IN NORDBADEN/GERMANY

    Nov 1, 2005, 00:00

  • PSN8 EXAMINATION OF ADHERENCE TO PHARMACOTHERAPY TREATMENT GUIDELINES IN PATIENTS WITH PSORIASIS IN THE UNITED STATES

    Nov 1, 2005, 00:00

  • PCV33 A COST-EFFECTIVENESS ANALYSIS OF LOW-DOSE ASPIRIN IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN FOUR EUROPEAN COUNTRIES

    Nov 1, 2005, 00:00

  • PAL2 ATTRIBUTES FOR PREFERENCE OF NEW FAST DISSOLVING TABLET (FDT) FORMULATION OF EBASTINE IN PATIENTS WITH ALLERGY

    Nov 1, 2005, 00:00

  • PRS20 PATIENT REPORTED IMPACT OF COUGH AND SPUTUM IN CHRONIC (OBSTRUCTIVE) BRONCHITIS—SIMULTANEOUS DEVELOPMENT OF THE SELF-ADMINISTERED CASA-Q

    Nov 1, 2005, 00:00

  • PIH11 WORKAND HEALTH CONDITIONS DURING PREGNANCY IN WOMEN OF THE MEXICAN SOCIAL SECURITY INSTITUTE

    Nov 1, 2005, 00:00

  • PCN39 APPLICATION OF AN ALGORITHM FOR DEFINING RETROSPECTIVE COHORTS OF COLORECTAL CANCER (CRC) PATIENTS TREATED WITH DIFFERENT FIRST-LINE CHEMOTHERAPY REGIMENS +/− BEVACIZUMABTO ADMINISTRATIVE CLAIMS DATA

    Nov 1, 2005, 00:00

  • PCN21 TREATMENT COST OF COLORECTAL CANCER CHEMOTHERAPIES IN GERMANY

    Nov 1, 2005, 00:00

  • PUK34 EVALUATION OF TWO TENSION FREE VAGINAL TAPES WITH URODYNAMICS AND ICIQ-UI SF QUESTIONNAIRE

    Nov 1, 2005, 00:00

  • PUK6 ECONOMIC IMPACT OF EXTENDED-RELEASE TOLTERODINE VERSUS IMMEDIATE-AND EXTENDED-RELEASE OXYBUTYNIN AMONG COMMERCIALLY-INSURED PERSONS WITH OVERACTIVE BLADDER

    Nov 1, 2005, 00:00

  • PGI21 BURDEN OF ILLNESS OF IBS PATIENTS IN THE NETHERLANDS

    Nov 1, 2005, 00:00

  • PDB37 COSTS OF STAYS OF CARDIOVASCULAR EVENTS OF DIABETIC PATIENTS IN THE FRENCH HOSPITALS

    Nov 1, 2005, 00:00

  • PMC11 DEVELOPMENT AND VALIDATION OF A CLAIMS-BASED RISK ASSESSMENT MODEL TO PREDICT PHARMACY EXPENDITURES IN A U.S. MEDICAID POPULATION

    Nov 1, 2005, 00:00

  • PFM4 DIAGNOSIS OF FIBROMYALGIA AND HEALTH CARE RESOURCE USE IN PRIMARY CARE IN THE UK

    Nov 1, 2005, 00:00

  • POB10 VALIDATION OF A PATIENT-REPORTED OUTCOMES QUESTIONNAIRE FOR ASSESSING POSITIVE WELL-BEING ASSOCIATED WITH BEHAVIORAL CHANGES

    Nov 1, 2005, 00:00

  • POB3 THE ECONOMIC BURDEN OF ADULT OBESITY, WITH SPECIAL REFERENCE TO DRUG CONSUMPTION- ESTIMATES FROM THE KORA STUDY REGION

    Nov 1, 2005, 00:00

  • PHP43 IMPACT OF PHARMACEUTICAL POLICIES ON PROMOTIONAL TARGETED DRUGS

    Nov 1, 2005, 00:00

  • PIN22 COST-UTILITY ANALYSIS OF A HYPOTHETICAL VACCINATION PROGRAM AMONG THE CURRENTLY TARGETED POPULATION IN THE NETHERLANDS IN CASE OF AN INFLUENZA PANDEMIC

    Nov 1, 2005, 00:00

  • PMC3 INTERNATIONAL VARIATION IN CLINICAL INJURY INCIDENCE- REAL OR ARTIFICIAL DIFFERENCES?

    Nov 1, 2005, 00:00

  • PHP7 MANAGING ACUTE INJURIES RESULTING FROM MOTORCYCLE ACCIDENTS- EMERGENCY DEPARTMENT AND INPATIENT HOSPITAL RESOURCE USE AND COSTS

    Nov 1, 2005, 00:00

  • Supplement- Empirical Explorations in the Green and Growing Field of Treatment Satisfaction

    Nov 1, 2005, 00:00

  • PNL5 A PROSPECTIVE STUDY ON THE IMPACT OF A CHILD'S EPILEPSY ON THEIR QUALITY OF LIFE AND THEIR FAMILY

    Nov 1, 2005, 00:00

  • PCV22 CASE-BASED-COSTING VS. MARKOV-MODELLING—A COMPARISON OF COST-EFFECTIVENESS-ANALYSES FOR CANDESARTAN IN PATIENTS WITH CHRONIC HEART FAILURE

    Nov 1, 2005, 00:00

  • PCN20 ORAL AND INTRAVENOUS CHEMOTHERAPY FOR FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE UK NHS SYSTEM

    Nov 1, 2005, 00:00

  • PIN24 ADDING A QUADRIVALENT (6, I I, 16 18 TYPES) HUMAN PAPILLOMAVIRUS VACCINE TO THE EXISTING UK CERVICAL SCREENING PROGRAMME IS POTENTIALLY COST-EFFECTIVE

    Nov 1, 2005, 00:00

  • PCN52 ASSESSING QOL IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) TREATED WITH CHEMOTHERAPY

    Nov 1, 2005, 00:00

  • IC4 ECONOMIC ANALYSIS OF THE STRATEGY STUDY- TIROFIBAN AND DRUG ELUTING STENTS VERSUS ABCIXIMAB AND BARE METAL STENTS

    Nov 1, 2005, 00:00

  • PEY12 PHARMACOECONOMIC ANALYSIS OF LATANOPROST VERSUS DORZOLAMIDE/TIMOLOL IN THE TREATMENT OF OPEN-ANGLE GLAUCOMA IN SPAIN

    Nov 1, 2005, 00:00

  • PMH17 HEALTH RELATED QUALITY OF LIFE (HRQOL) AND BURDEN OF FAMILY CAREGIVERS OF DIALYSIS PATIENTS

    Nov 1, 2005, 00:00

  • PCV4 HOW MUCH IS THE ACUTE CORONARY SYNDROMES IN-HOSPITAL THERAPY- A PILOT STUDY ON THERAPY

    Nov 1, 2005, 00:00

  • PMC15 DIRECT AND INDIRECT COSTS AND EFFECTS IN COST-EFFECTIVENESS ANALYSIS OF PREVENTION- A DYNAMIC MODELLING ANALYSIS

    Nov 1, 2005, 00:00

  • PGI8 ECONOMIC EVALUATION OF ADACOLUMN® APHERESIS FOR THE TREATMENT OF PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE (CD)/ULCERATIVE COLITIS (UC)

    Nov 1, 2005, 00:00

  • DN2 COST-UTILITY ANALYSIS IN A UK SETTING OF SELF MONITORING OF BLOOD GLUCOSE IN PATIENTS WITH TYPE-2 DIABETES

    Nov 1, 2005, 00:00

  • PMC4 THE CONTRIBUTION OF PREVENTION AND MEDICAL CARE TO POPULATION HEALTH

    Nov 1, 2005, 00:00

  • PCN13 COST-EFFECTIVENESS OF HEPATIC ARTERY INFUSION FOR METASTATIC COLORECTAL CANCER (CALGB 9481)

    Nov 1, 2005, 00:00

  • PHP27 PREDICTIVE VALUE OF PHARMACEUTICAL TREATMENT (PT) COST AND LENGTH OF STAY (LOS) ON TOTAL HOSPITAL (TH) COST USING THE MINIMUM BASIC DATA SET (MBDS)

    Nov 1, 2005, 00:00

  • PCV80 COST ESTIMATION IN PATIENTS WITH AN ATHEROTROMBOTIC EVENT

    Nov 1, 2005, 00:00

  • PMH46 COST-EFFECTIVENESS ANALYSIS OF ESCITALOPRAM IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN GERMANY

    Nov 1, 2005, 00:00

  • PHP10 THE IMPACT OF MEDICARE MANAGED CARE ON USE OF VA PHARMACY SERVICES

    Nov 1, 2005, 00:00

  • PAS8 ASTHMA RELATED QUALITY OF LIFE IS CORRELATED WITH ASTHMA CONTROL AMONG RESPIRE STUDY PARTICIPANTS

    Nov 1, 2005, 00:00

  • MC4 UNCONDITIONAL POWER FOR SECONDARY OBJECTIVES IN A CLINICAL TRIAL

    Nov 1, 2005, 00:00

  • PMH47 COST OF AFFECTIVE DISORDERS IN EUROPE

    Nov 1, 2005, 00:00

  • PCV40 HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH CORONARY HEART DISEASE- A STUDY USING EQ-5D QUESTIONNAIRE

    Nov 1, 2005, 00:00

  • PGI17 ARTIFICIAL LIVER SUPPORT SYSTEMS—A MEDICAL AND HEALTH ECONOMIC HTA-REPORT

    Nov 1, 2005, 00:00

  • PCV59 PHARMACO-ECONOMIC ANALYSIS OF VALSARTAN/HYDROCHLOROTHIAZIDE (HCTZ)VERSUS CANDESARTAN/HCTZ AND VERSUS TELMISARTAN/HCTZ IN THE TREATMENT OF SYSTEMIC ARTERIAL HYPERTENSION IN MEXICO

    Nov 1, 2005, 00:00

  • PHP22 EFFECTS OF DECENTRALIZED RESPONSIBILITY FOR COSTS OF OUTPATIENT PRESCRIPTION DRUGS ON THE PHARMACEUTICAL COST DEVELOPMENT IN SWEDEN

    Nov 1, 2005, 00:00

  • PRS7 COST-EFFECTIVENESS OF FENSPIRIDE IN ADULTS WITH CHRONIC BRONCHITIS EXACERBATIONS IN POLAND

    Nov 1, 2005, 00:00

  • PMC9 THE OPTIMAL COST-EFFECTIVENESS RATIO THRESHOLD IN CASE OF CO-MORBIDITIES

    Nov 1, 2005, 00:00

  • PDB33 COST-CONSEQUENCE ANALYSIS OF SCREENING AND OPTIMIZED TREATMENT OF NEPHROPATHY IN HYPERTENSIVE PATIENTS WITH TYPE-2 DIABETES INA FRENCH SETTING

    Nov 1, 2005, 00:00

  • PUK36 PATIENT SATISFACTION- PSYCHOMETRIC VALIDATION OF THE OAB-S, AN OVERACTIVE BLADDER TREATMENT SATISFACTION QUESTIONNAIRE.

    Nov 1, 2005, 00:00

  • PDB55 MEASURING QUALITY OF LIFE WITH EQ-5D IN AN AUSTRIAN OUTPATIENT CLINIC FOR PATIENTS WITH DIABETES MELLITUS

    Nov 1, 2005, 00:00

  • Using a Treatment Satisfaction Measure in an Early Trial to Inform the Evaluation of a New Treatment for Benign Prostatic Hyperplasia

    Nov 1, 2005, 00:00

  • PCV66 PATIENTS ON ARBS (AND VALSARTAN AS A REPRESENTATIVE) EXPERIENCE HIGHER PERSISTENCE AND COMPLIANCE (ADHERENCE) WITH THERAPY COMPARED TO OTHER ANTIHYPERTENSIVE CLASSES IN A GERMAN SICKNESS FUND POPULATION

    Nov 1, 2005, 00:00

  • PSN24 ATOPIC DERMATITIS- A CONJOINT ANALYSIS PILOT STUDY

    Nov 1, 2005, 00:00

  • PHP17 EFFECTS OF GENERIC SUBSTITUTION ON THE DEVELOPMENT OF PHARMACEUTICAL EXPENDITURES DURING THE PERIOD JANUARY I 998 TO MAY 2005

    Nov 1, 2005, 00:00

  • PMC23 ECONOMIC EVALUATION OF MEDICAL DEVICES IN FRANCE- A CHALLENGE FOR HEALTH ECONOMISTS

    Nov 1, 2005, 00:00

  • PCV62 LIPID PROFILE IN HYPERTENSIVES WITH AND WITHOUT CARDIOVASCULAR DISEASE- HAS THE HDL COLESTEROL BEEN FORGOTTEN?

    Nov 1, 2005, 00:00

  • PMC13 ECONOMIC IMPACT OF HOSPITAL MALNUTRITION

    Nov 1, 2005, 00:00

  • PDB4 HEALTH CARE UTILIZATION AND EXPENDITURES ASSOCIATED WITH USE OF INSULIN GLARGINE

    Nov 1, 2005, 00:00

  • PRS3 COST ANALYSIS OF FOURTREATMENT STRATEGIES IN THE MANAGEMENT OF MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE- AN APPLICATION ON NON-PARAMETRIC BOOTSTRAP

    Nov 1, 2005, 00:00

  • PIN18 DETERMINANTS OF HEALTH CARE COSTS IN AMBULATORY PATIENTS LIVING WITH HIV/AIDS

    Nov 1, 2005, 00:00

  • PGI1 CLINICAL OUTCOMES OF RABEPRAZOLE IN PATIENTS WITH GASTRO-OESOPHAGEAL REFLUX DISEASE IN REAL-WORLD CLINICAL PRACTICE

    Nov 1, 2005, 00:00

  • PIN16 MEDICAL COSTS ASSOCIATED WITH NON-ADHERENCE TO ANTIRETROVIRAL THERAPY IN HIV-POSITIVE PATIENTS

    Nov 1, 2005, 00:00

  • PSN15 QUALITY OF LIFE IMPROVEMENT AS MEASURED BY EQ-5D IS CONSISTENT WITH CLINICAL RESPONSE IN MODERATE TO SEVERE PLAQUE PSORIASIS PATIENTS TREATED WITH ADALIMUMAB

    Nov 1, 2005, 00:00

  • PCV49 BELGIAN EVALUATION OF SCREENING AND TREATMENT OF HIGH RISK PATIENTS BASED ON WAIST AND AGE (BEST)

    Nov 1, 2005, 00:00

  • POS4 COST-EFFECTIVENESS OF PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS WITH ALENDRONATE ORALFACALCIDOL.THE STOP-STUDY- A RANDOMIZED PLACEBO-CONTROLLED TRIAL

    Nov 1, 2005, 00:00

  • PUK3 CLINICAL IMPACT OF NONCOMPLIANCE AFTER RENAL TRANSPLANTATION

    Nov 1, 2005, 00:00

  • PCN53 MONITORING AND SECURING QUALITY IN ONCOLOGICAL CARE—THE 2004 LONGITUDINAL PASQOC® RESULTS

    Nov 1, 2005, 00:00

  • PDB39 EVALUATION OF THE COST-UTILITY OF INSULIN DETEMIR COMPARED TO INSULIN GLARGINE, BOTH IN COMBINATION WITH INSULIN ASPART INTYPE-I DIABETES IN GERMANY AND AUSTRIA

    Nov 1, 2005, 00:00

  • PDB40 COST-UTILITY ANALYSIS IN A USA SETTING OF SCREENING AND OPTIMIZED TREATMENT OF NEPHROPATHY IN HYPERTENSIVE PATIENTS WITH TYPE-2 DIABETES

    Nov 1, 2005, 00:00

  • PIH12 QUALITY OF LIFE AND HEALTH BEHAVIORS OF VENEZUELAN PHARMACY STUDENTS

    Nov 1, 2005, 00:00

  • PMH34 LONG-TERM TREATMENT OF SCHIZOPHRENIA FOR RELAPSE PREVENTION (LASER)- 6-MONTH OUTCOMES IN PATIENTS STARTED ON RISPERIDONE LONG-ACTING INJECTABLE IN GERMANY—DATA FROM THE E-STAR DATABASE

    Nov 1, 2005, 00:00

  • PDB53 INTERNAL VALIDATION OF THE ECONOMIC ASSESSMENT OF GLYCEMIC CONTROL AND LONG-TERM EFFECTS (EAGLE) DIABETES MODEL

    Nov 1, 2005, 00:00

  • PGI13 THE IMPACT OF GASTROESOPHAGEAL REFLUX DISEASE ON WORK PRODUCTIVITY- A SYSTEMATIC REVIEW

    Nov 1, 2005, 00:00

  • PDB31 A LIFETIME MODELLED ECONOMIC EVALUATION COMPARING PIOGLITAZONE AND ROSIGLITAZONE FORTHE TREATMENT OF TYPE-2 DIABETES MELLITUS IN THE UK

    Nov 1, 2005, 00:00

  • PMH14 DUTCH ADAPTION OF THE COST-EFFECTIVENESS OF QUETIAPINE IN COMBINATION THERAPY IN THE MANAGEMENT OF ACUTE MANIA IN BIPOLAR I DISORDER

    Nov 1, 2005, 00:00

  • PIN11 A RETROSPECTIVE EVALUATION OF THE MANAGEMENT AND OUTCOME IN HOSPITALIZED PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA IN AN INNER-CITY HOSPITAL

    Nov 1, 2005, 00:00

  • MC6 PERFORMANCE OF THE DMM SIMULATION MODEL IN PREDICTING REAL WORLD CHANGES IN GLYCEMIC CONTROL FOLLOWING DIAGNOSIS OF DIABETES

    Nov 1, 2005, 00:00

  • A Comparison of Self-Selectivity Corrections in Economic Evaluations and Outcomes Research

    Nov 1, 2005, 00:00

  • PCV67 FACTORS DETERMINING COMPLIANCE IN PATIENTS WITH HIGH CARDIOVASCULAR RISK IN DAILY CLINICAL PRACTICE

    Nov 1, 2005, 00:00

  • PMH8 THE HEATLH-RELATED QUALITY OF LIFE OF CHILDREN SUFFERING FROM ADHD AND THE COSTS TO SOCIETY

    Nov 1, 2005, 00:00

  • PAR16 POTENTIAL PROBLEMS IN USING RCT DATA TO ESTIMATE COST-EFFECTIVENESS- RESULTS FROM AN ANALYSIS OF ETANERCEPT USE IN RHEUMATOID ARTHRITIS

    Nov 1, 2005, 00:00

  • PMC25 ANALYSIS OF QUALITY OF LIFE DATA FROM DIFFERENT UTILITY INSTRUMENTS—AN EXAMPLE USING IMPUTATION

    Nov 1, 2005, 00:00

  • PPN2 THE COST-EFFECTIVENESS OF STRONG, CONTROLLED-RELEASE OPIOIDS FOR THE TREATMENT OF CHRONIC NON-MALIGNANT PAIN- A PROBABILISTIC DECISION-MODEL

    Nov 1, 2005, 00:00

  • PIN25 PRELIMINARY COST-EFFECTIVENESS ANALYSIS OF A POTENTIAL PROPHYLACTIC STHAPHYLOCOCCUS AUREUS VACCINE (STAPHVAX) IN HEMODIALYSIS PATIENTS IN GERMANY

    Nov 1, 2005, 00:00

  • PCN45 MULTILINGUAL VALIDATION OF THE FACT-LEUKEMIA IN 7 LANGUAGES

    Nov 1, 2005, 00:00

  • MC8 THE APPLICATION OF BAYESIAN METHODS TO EVALUATE THE IMPACT OF TIME-DELAY ON THE COST-EFFECTIVENESS OF PRIMARY ANGIOPLASTY FOR ACUTE MYOCARDIAL INFARCTION

    Nov 1, 2005, 00:00

  • PNL2 COST-EFFECTIVENESS OF ADDING MEMANTINE TREATMENT TO PATIENTS RECEIVING STABILISED DOSES OF DONEPEZIL IN THE UK

    Nov 1, 2005, 00:00

  • PPN7 COST-EFFECTIVENESS ANALYSIS OF THE COMBINATION TRAMADOL PLUS PARACETAMOL VERSUS CODEINE PLUS PARACETAMOL FOR POSTOPERATIVE PAIN THERAPY IN THE NETHERLANDS

    Nov 1, 2005, 00:00

  • PAS9 THE SPANISH VERSION OF THE MINI-ASTHMA QUALITY OF LIFE QUESTIONNAIRE- EXAMINATION OF RESPONSIVENESS TO CHANGE

    Nov 1, 2005, 00:00

  • PRS5 PHARMACOECONOMIC EVALUATION OFTIOTROPIUM IN THE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN SPAIN

    Nov 1, 2005, 00:00

  • PMH45 COST EFFECTIVENESS OF DULOXETINE COMPARED WITH VENLAFAXINE-XR IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER

    Nov 1, 2005, 00:00

  • PCV13 EPIDEMIOLOGY AND COSTS OF ATRIAL TACHYARRHYTMIAS

    Nov 1, 2005, 00:00

  • PSN19 QUALITY OF LIFE OF PAEDIATRIC PATIENTS WITH ATOPIC ECZEMAANDTHEIR FAMILIES

    Nov 1, 2005, 00:00

  • PCV42 RECENT TREND IN MANAGEMENT OF HYPERCHOLESTEROLEMIA AND GOAL ATTAINMENT

    Nov 1, 2005, 00:00

  • PDB51 EVALUATING INTERVENTIONS ALONG THE COURSE OF DISEASE- MODELING DIABETES AND ITS MACROVASCULAR COMPLICATIONS

    Nov 1, 2005, 00:00

  • PIN12 ASSESSEMENT OF THE EFFECT OF DROTRECOGIN ALPHA (ACTIVATED)TREATMENT OF SEVERE SEPSIS ON BLEEDING EVENTS WITH COUNT MODELS

    Nov 1, 2005, 00:00

  • PCN50 A PILOT STUDY ASSESSING THE QUALITY OF LIFE IMPACT OF ADVERSE EVENTS EXPERIENCED BY ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS RECEIVING SECOND-LINE CHEMOTHERAPY

    Nov 1, 2005, 00:00

  • IN3 COST-EFFECTIVENESS OF VORICONAZOLE VERSUS LIPOSOMALAMPHOTERICIN B FOR INVASIVE ASPERGILLOSIS INFECTION IN THE UK

    Nov 1, 2005, 00:00

  • PR3 BIPOLAR PATIENTS' STATED THERAPY PREFERENCES AND LIKELY ADHERENCE

    Nov 1, 2005, 00:00

  • PMH32 NEUROLEPTIC TREATMENT OF SCHIZOPHRENIA IN AMBULATORY CARE IN GERMANY

    Nov 1, 2005, 00:00

  • UH2 COST DRIVERS IN MULTIPLE MYELOMA TREATMENT—A 2 YEAR ANALYSIS FROM A MULTICOUNTRY RETROPROJECTED CHART REVIEW

    Nov 1, 2005, 00:00

  • PMC14 POPULATION KNOWLEDGE- AN APPROACH TO CLASSIFY A GENERAL POPULATION ACCORDING TO LIFESTYLE, HEALTH BEHAVIOUR AND ATTITUDE

    Nov 1, 2005, 00:00

  • PUK35 VALIDATION OF THE SYMPTOM FREQUENCY AND BOTHERSOMENESS SCALE FOR STRESS URINARY INCONTINENCE (SFB-SUI) IN A BRITISH POPULATION

    Nov 1, 2005, 00:00

  • PHP29 REIMBURSEMENT OF HIGH-PRICED NEW EMERGING MEDICAL TECHNOLOGIES IN A DRG-BASED HOSPITAL CARE SYSTEM

    Nov 1, 2005, 00:00

  • PNL20 DISEASE SEVERITY AND HEALTH CARE COSTS OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN PORTUGAL

    Nov 1, 2005, 00:00

  • PCN42 MODELLING THE EFFECT OF A NOVEL THERAPEUTIC AGENT ON THE EVOLUTION OF UTILITY IN REFRACTORY MULTIPLE MYELOMA PATIENTS

    Nov 1, 2005, 00:00

  • PDB58 DIABETIC PERIPHERAL NEUROPATHY- EVALUATION OF THE ASSOCIATION BETWEEN NEUROPATHIC SYMPTOMS (NTSS-6-SA) AND HEALTH-RELATED UTILITY (EQ5D)

    Nov 1, 2005, 00:00

  • PCV43 IMPACT OF NEW EUROPEAN (ESC 2003) GUIDELINES ON TREATMENT OF HYPERCHOLESTEROLEMIA IN DAILY PRACTICE

    Nov 1, 2005, 00:00

  • PPN5 A MODEL-BASED COST-UTILITY ANALYSIS OF LYRICA™(PREGABALIN) VERSUS CURRENT PHARMACEUTICAL MANAGEMENT OF PERIPHERAL NEUROPATHIC PAIN

    Nov 1, 2005, 00:00

  • PCV12 MANAGEMENT PATTERNS AND COSTS OF ATRIAL FIBRILLATION IN A LARGE COMMERCIALLY INSURED U.S. POPULATION

    Nov 1, 2005, 00:00

  • DN4 PHARMACOECONONOMIC EVALUATION OF SEDATION WITH REMIFENTANIL/PROPOFOLVERSUS MIDAZOLAM/FENTANYL IN THE INTENSIVE CARE UNIT

    Nov 1, 2005, 00:00

  • PCV46 COST-ANALYSIS OF HYPERCHOLESTEROLEMIATREATMENTS WITHIN THE SLOVAK PHARMACEUTICAL MARKET

    Nov 1, 2005, 00:00

  • QL7 IMPACT OF LUTS ON QUALITY OF LIFE IN ITALIAN WOMEN

    Nov 1, 2005, 00:00

  • PCN23 ECONOMIC ASPECTS AND DRIVERS OF FEBRILE NEUTROPENIA IN CANCER—A MULTICENTRE RETROSPECTIVE ANALYSIS IN BELGIUM

    Nov 1, 2005, 00:00

  • PMH27 12-MONTH COST-EFFECTIVENESS ANALYSIS OF ORAL ANTIPSYCHOTIC TREATMENTS IN PATIENTS WITH SCHIZOPHRENIA IN THE PAN-EUROPEAN SOHO (SCHIZOPHRENIA OUTPATIENT HEALTH OUTCOMES) STUDY

    Nov 1, 2005, 00:00

  • PCV75 COST-EFFECTIVENESS OF EPTIFIBATIDE IN NSTEMI PATIENTS IN POLAND

    Nov 1, 2005, 00:00

  • PSN12 NAIL PSORIASIS- ELABORATION OF A SCALE FOR FUNCTIONAL DISCOMFORT

    Nov 1, 2005, 00:00

  • PCN15 PHARMACOECONOMIC ANALYSIS OF EXEMESTANE VERSUS TAMOXIFEN AS ADJUVANT THERAPY FOR PATIENTS WITH EARLY-STAGE ESTROGEN RECEPTOR-POSITIVE BREAST CANCER

    Nov 1, 2005, 00:00

  • PCN2 LEAD TIME IN THE EVALUATION OF HISTORICAL SURVIVAL IMPROVEMENTS IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER

    Nov 1, 2005, 00:00

  • PIN30 INCIDENCE, PREVALENCE AND COSTS OF TREATING GENITAL WARTS IN THE PRE-HPVVACCINE ERA IN GERMANY, 2005

    Nov 1, 2005, 00:00

  • IN4 LOWERING THE AGE THRESHOLD FOR ROUTINE INFLUENZA VACCINATION- AN ECONOMIC EVALUATION FOR FOUR EUROPEAN COUNTRIES

    Nov 1, 2005, 00:00

  • PCV73 USE OF PROPENSITY SCORE METHODOLOGY IN CARDIOVASCULAR DEVICE TRIALS- U.S. FOOD AND DRUG ADMINISTRATION PERSPECTIVES

    Nov 1, 2005, 00:00

  • POS5 THE COST-EFFECTIVENESS OF RISENDRONATE COMPARED TO ALENDRONATE IN POST-MENOPAUSAL WOMEN WITH ESTABLISHED OSTEOPOROSIS- A POLISH ANALYSIS

    Nov 1, 2005, 00:00

  • PDB47 TYPE-2 DIABETES AND GLYCEMIC CONTROL IN GERMANY

    Nov 1, 2005, 00:00

  • PEY1 ANXIETY AND DEPRESSION IN WET AGE-RELATED MACULAR DEGENERATION (ARMD)

    Nov 1, 2005, 00:00

  • PCV63 CARDIOVASCULAR DRUG USE IN NIS REGION

    Nov 1, 2005, 00:00

  • PDB36 COST OF TYPE-2 DIABETES MELLITUS IN HONG KONG CHINESE

    Nov 1, 2005, 00:00

  • PHM2 THE COST OF CARE OF HEMOPHILIC PATIENTS WITHOUT INHIBITORS- THE COCHE STUDY

    Nov 1, 2005, 00:00

  • PHP30 PRESCRIBING PATTERNS AND ASSOCIATED COSTS OF PSYCHOTROPIC DRUGS IN A MAJOR HEALTH CARE SYSTEM IN SAUDI ARABIA

    Nov 1, 2005, 00:00

  • PSU3 THE COST OF ANTIBIOTIC THERAPY IN PATIENTS UNDERGOING COLORECTAL SURGERY

    Nov 1, 2005, 00:00

  • PCN40 DEVELOPMENT OF AN ALGORITHM FOR THE IDENTIFICATION AND CLASSIFICATION OF COLORECTAL CANCER (CRC) PATIENTS ACCORDING TO FIRST-LINE CHEMOTHERAPY +/− BEVACIZUMAB, AND INITIATION OF SECOND-LINE THERAPY USING ADMINISTRATIVE CLAIMS RECORDS

    Nov 1, 2005, 00:00

  • CO4 A COMPARISON OF LOGISTIC REGRESSION AND COX PROPORTIONAL HAZARDS MODELS FOR IDENTIFICATION OF RISK FACTORS FOR RENAL IMPAIRMENT IN HORMONE REFRACTORY PROSTATE CANCER (HRPC) PATIENTS WITH BONE METASTASES (BM) TREATED WITH ZOLEDRONIC ACID ...

    Nov 1, 2005, 00:00

  • PMC17 RASCH ANALYSIS OF THE FATIGUE IMPACT SCALE

    Nov 1, 2005, 00:00

  • PMC18 PSYCHOMETRIC PROPERTIES OF A TOUCH SCREEN COMPUTER-BASED VERSION OF THE SF-36

    Nov 1, 2005, 00:00

  • PCV52 IMPACT OF COMPLIANCE AND PERSISTENCE OF TREATMENT WITH VALSARTAN ON HYPERTENSION CLINICAL OUTCOMES

    Nov 1, 2005, 00:00

  • PMH6 TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)- ARE U.S. COST-EFFECTIVENESS FINDINGS BASED UPON THE MTA STUDY RELEVANTTO MENTAL HEALTH CARE POLICY MAKERS IN GERMANY?

    Nov 1, 2005, 00:00

  • PRS11 MANAGEMENT OF COPD IN BELGIUM- A REAL LIFE COST OF ILLNESS STUDY

    Nov 1, 2005, 00:00

  • PUK28 LONG-TERM DARIFENACIN TREATMENT FOR OVERACTIVE BLADDER- QUALITY OF LIFE OUTCOMES FROM A 2-YEAR, OPEN-LABEL EXTENSION STUDY

    Nov 1, 2005, 00:00

  • PHP8 RESOURCE CONSUMPTION IN PLATELET PRODUCTION FROM THE PERSPECTIVE OF A TRANSFUSION MEDICINE DEPARTMENT IN GERMANY

    Nov 1, 2005, 00:00

  • PAS7 THE HUMAN IMPACT OF SEVERE PERSISTENT ALLERGIC ASTHMA- RESULTS FROM A MULTINATIONAL STUDY

    Nov 1, 2005, 00:00

  • DN3 COST-EFFECTIVENESS OF NON-INVASIVE IMAGING IN THE DIAGNOSIS OF PARKINSONISM

    Nov 1, 2005, 00:00

  • PMD3 A COST EFFECTIVENESS MODEL FOR THE EVALUATION OF TOTAL HIP ARTHROPLASTY (THA) AND TOTAL KNEE ARTHROPLASTY (TKA) IN SWEDEN

    Nov 1, 2005, 00:00

  • PGI9 COST-EFFECTIVENESS OF ESOMEPRAZOLE VERSUS GENERIC OMEPRAZOLE IN THE ACUTE TREATMENT OF REFLUX ESOPHAGITIS IN SWEDEN

    Nov 1, 2005, 00:00

  • PHP32 COMBINING PHARMACY AND HOSPITAL DATA IN A RISK ADJUSTMENT MODEL

    Nov 1, 2005, 00:00

  • PNL3 RETROSPECTIVE COMPARATIVE ANALYSIS OF ANTIDEMENTIA MEDICATION PERSISTENCE PATTERNS AT 3 YEARS IN SPANISH ALZHEIMER DISEASE PATIENTS TREATED WITH DONEPEZIL, RIVASTIGMINE, GALANTAMINE AND MEMANTINE

    Nov 1, 2005, 00:00

  • PHP20 GENERIC DRUG PRICES REMAIN HIGHER IN CANADA THAN IN THE UNITED STATES

    Nov 1, 2005, 00:00

  • PDB62 TREATMENT SATISFACTION IN SUBJECTS WITH TYPE-2 DIABETES RECEIVING INSULIN GLARGINE

    Nov 1, 2005, 00:00

  • PEY21 UTILITY ASSESSMENT AMONG PATIENTS WITH DRY EYE DISEASE IN THE UK

    Nov 1, 2005, 00:00

  • PST9 MANDARIN VERSION OF STROKE IMPACT SCALE- ADAPTATION AND VALIDATION

    Nov 1, 2005, 00:00

  • PIN27 COST-MINIMIZATION ANALYSIS OF VORICONAZOLE AND LIPOSOMALAMPHOTERICIN B FOR THE TREATMENT OF INVASIVE CANDIDA AND ASPERGILLOSIS INFECTIONS IN SPAIN

    Nov 1, 2005, 00:00

  • PGI23 ESOMEPRAZOLE TREATMENT IN PATIENTS WITH UNINVESTIGATED NON-GERD DYSPEPSIA LEADS TO SIGNIFICANT IMPROVEMENTS IN PRODUCTIVITYWHILE ATWORKAND IN DAILY ACTIVITIES—RESULTS FROMA RANDOMISED, PLACEBO-CONTROLLED CLINICAL STUDY

    Nov 1, 2005, 00:00

  • PAR1 COSTS AND EFFECTS OF CELECOXIB IN THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS IN THE NETHERLANDS

    Nov 1, 2005, 00:00

  • PHP34 EFFECTS OF MEDICAL SAVINGS ACCOUNTS ON HEALTH CARE UTILIZATION AND HEALTH EXPENDITURE- EVIDENCE FROM CHINA

    Nov 1, 2005, 00:00

  • PUK19 EXPLORING NEUROGENIC DETRUSOR OVERACTIVITY WITHIN AN OVERACTIVE BLADDER POPULATION

    Nov 1, 2005, 00:00

  • PMD2 COST-EFFECTIVENESS ANALYSIS OF ACLASTA IN PAGET'S DISEASE OF BONE IN BELGIUM

    Nov 1, 2005, 00:00

  • PGI19 GASTROESOPHAGEAL REFLUX DISEASE (GERD) COST OF CARE- ROLE OF NAÏVE AND RELAPSED SYMPTOMS IN GENERAL PRACTICE

    Nov 1, 2005, 00:00

  • PNL8 COST-EFFECTIVENESS OF BETAHISTINE VS CINNARIZINE FOR VERTIGO

    Nov 1, 2005, 00:00

  • PNL7 IS THE TREATMENT OF ACUTE MIGRAINE WITH TRIPTANS EFFICIENT FROM A SOCIETAL PERSPECTIVE?

    Nov 1, 2005, 00:00

  • PIN14 IMPACT ON QUALITY OF LIFE OF HEALTH STATES INDUCED BY CHRONIC HEPATITIS B INFECTION- ESTIMATES FROM INFECTED AMERICANS

    Nov 1, 2005, 00:00

  • PEY2 USE OF NEURAL NETWORKS TO PREDICT NIGHT INTRA-OCULAR PRESSURE (IOP) PEAK CONTROL BY PROSTAGLANDIN ANALOGUES

    Nov 1, 2005, 00:00

  • PCV28 IMPACT OF MODIFIED SYSTEM OF OBJECTIFIED JUDGMENT ANALYSIS (SOJA) METHODOLOGY ON PRESCRIBING COSTS OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACEIS)

    Nov 1, 2005, 00:00

  • PSN17 VALIDATION OF THE ITALIAN VERSION OF THE INFANTS' DERMATITIS QUALITY OF LIFE FAMILY DERMATITIS INDEXES

    Nov 1, 2005, 00:00

  • QL3 “FAMIDIAL STUDY”- ANALYSIS OF THE DIFFERENCES BETWEEN DIALYSIS PATIENTS AND THEIR CAREGIVERS (FAMILY CARERS, NURSES AND DOCTORS) ON DIALYSIS PATIENTS' HRQOL, AND OF THE FAMILY CARERS' HRQOL AND BURDEN

    Nov 1, 2005, 00:00

  • PPN10 PSYCHOMETRIC PROPERTIES OF THE MOS-SLEEP SCALE IN NEUROPATHIC PAIN (NEP) SYNDROMES

    Nov 1, 2005, 00:00

  • POB2 PREVALENCE TRENDS IN OVERWEIGHT AND OBESITY AND WEIGHT CONTROL PRACTICES AMONG ADULTS IN THE US

    Nov 1, 2005, 00:00

  • PHP48 A SURVEY OF PATIENT REPORTED OUTCOME (PRO) CLAIMS IN PHARMACEUTICAL ADVERTISING

    Nov 1, 2005, 00:00

  • PCN9 COST COMPARISON ANALYSIS OF INTRAVENOUS VERSUS COMBINED INTRAVENOUS-ORAL CHEMOTHERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER

    Nov 1, 2005, 00:00

  • PIN21 SELF ASSESSED HEALTH-RELATED QUALITY OF LIFE AMONG HIV PATIENT IN UK

    Nov 1, 2005, 00:00

  • PGI18 META-ANALYSIS OF MULTIPLE TREATMENT COMPARISONS REPORTED AT MULTIPLE FOLLOW-UP TIMES

    Nov 1, 2005, 00:00

  • PEY15 COST OF ENDOPHTHALMITIS- A NATIONWIDE APPROACH

    Nov 1, 2005, 00:00

  • PCV45 THE ECONOMIC ASSESSMENT OF SWITCHING TO DUAL INHIBITION CHOLESTEROL LOWERING THEARPY IN FINLAND

    Nov 1, 2005, 00:00

  • PDB43 SHOULD WE LOOK FOR A NEWAPPROACH IN DIABETES MELLITUS (DM) MANAGEMENT? IS IT A COST-EFFECTIVE STRATEGY IN THE POLISH SETTING?

    Nov 1, 2005, 00:00

  • QL4 VARIABILITY IN QOL QUESTIONNAIRES AND THE HANDLING OF MISSING DATA IN PATIENTS WITH NON-SMALL CELL LUNG CANCER TREATED WITH CHEMOTHERAPY

    Nov 1, 2005, 00:00

  • PGI11 IBD- INDIRECT COSTS OF ILLNESS AND QUALITY OF LIFE IN GERMANY

    Nov 1, 2005, 00:00

  • PMH44 DULOXETINE AND VENLAFAXINE-XR IN THE TREATMENT OF MDD- A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS

    Nov 1, 2005, 00:00

  • PIN26 COST-EFFECTIVENESS OF PREVENTING OF RECURRENT UPPER RESPIRATORYTRACT INFECTIONS WITH NONSPECIFIC IMMUNOSTIMULATING BACTERIAL EXTRACT

    Nov 1, 2005, 00:00

  • PUK11 COST ANALYSIS OF RENAL REPLACEMENT THERAPIES IN LATVIA

    Nov 1, 2005, 00:00

  • PSN13 REFINEMENT AND REDUCTION OF THE IMPACT OF PSORIASIS QUESTIONNAIRE- CLASSICAL TEST THEORY VS RASCH ANALYSIS

    Nov 1, 2005, 00:00

  • POS2 CLINICAL EFFICACY AND SAFETY OF BALLOON KYPHOPLASTY FOR THE TREATMENT OF VERTEBRAL COMPRESSION FRACTURES- A SYSTEMATIC REVIEW OF THE LITERATURE

    Nov 1, 2005, 00:00

  • PMH12 THE NORDBADEN PROJECT FOR HEALTH CARE UTILIZATION RESEARCH IN GERMANY

    Nov 1, 2005, 00:00

  • QL8 QUALITY OF LIFE IN HEMOPHILIC PATIENTS WITHOUT INHIBITORS- THE COCHE STUDY

    Nov 1, 2005, 00:00
  • «
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159 (current)
  • 160
  • »